ASX - By Stock
|
SPL |
Starpharma: Patience Needed, But A Lot To Like
|
|
UTexas80
|
1 |
992 |
6 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
1
|
992
|
6
|
|
ASX - By Stock
|
SPL |
Early Stage COVID Treatments: Merck's Molnupiravir Struggles
|
|
UTexas80
|
1 |
835 |
16 |
04/12/21 |
04/12/21 |
ASX - By Stock
|
1
|
835
|
16
|
|
ASX - By Stock
|
SPL |
Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma
|
|
UTexas80
|
35 |
10K |
29 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
35
|
10K
|
29
|
|
ASX - By Stock
|
SPL |
Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
|
|
UTexas80
|
10 |
3.6K |
37 |
21/06/21 |
21/06/21 |
ASX - By Stock
|
10
|
3.6K
|
37
|
|
ASX - By Stock
|
SPL |
Re:
Viraleze marketing
|
|
UTexas80
|
169 |
53K |
3 |
11/04/21 |
11/04/21 |
ASX - By Stock
|
169
|
53K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Is Viraleze selling like hot cakes
|
|
UTexas80
|
813 |
278K |
0 |
05/04/21 |
05/04/21 |
ASX - By Stock
|
813
|
278K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is Viraleze selling like hot cakes
|
|
UTexas80
|
813 |
278K |
1 |
05/04/21 |
05/04/21 |
ASX - By Stock
|
813
|
278K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Is Viraleze selling like hot cakes
|
|
UTexas80
|
813 |
278K |
7 |
03/04/21 |
03/04/21 |
ASX - By Stock
|
813
|
278K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Is Viraleze selling like hot cakes
|
|
UTexas80
|
813 |
278K |
24 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
813
|
278K
|
24
|
|
ASX - By Stock
|
SPL |
Keith Williams: Starpharma Up With News, Down With None; Timing Entry Makes Sense
|
|
UTexas80
|
1 |
1.0K |
20 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
1
|
1.0K
|
20
|
|
ASX - By Stock
|
SPL |
Re:
SPL chart
|
|
UTexas80
|
451 |
142K |
1 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
451
|
142K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
SPL chart
|
|
UTexas80
|
451 |
142K |
3 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
451
|
142K
|
3
|
|
ASX - By Stock
|
SPL |
Auris Medical skyrockets 480% after announcing lab-test results that show its nasal spray could prot
|
|
UTexas80
|
9 |
3.2K |
0 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
9
|
3.2K
|
0
|
|
ASX - By Stock
|
SPL |
Will COVID Disappear Soon Or Do Investors Need To Pay Attention?
|
|
UTexas80
|
0 |
780 |
4 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
0
|
780
|
4
|
|
ASX - By Stock
|
SPL |
Quants Rewrite Stock Trades to Find Trillions in Hidden Assets
|
|
UTexas80
|
0 |
368 |
3 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
0
|
368
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
|
|
UTexas80
|
130 |
46K |
2 |
16/09/20 |
16/09/20 |
ASX - By Stock
|
130
|
46K
|
2
|
|
ASX - By Stock
|
SPL |
Got a breaking news alert from Seeking Alpha..
|
|
UTexas80
|
0 |
479 |
8 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
0
|
479
|
8
|
|
ASX - By Stock
|
SPL |
SPL ARIMA Forecast
|
|
UTexas80
|
2 |
1.2K |
0 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
2
|
1.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
The Golden Cross for Starpharma is now complete through 5-20-50-100-200 day averages
|
|
UTexas80
|
13 |
6.5K |
4 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
13
|
6.5K
|
4
|
|
ASX - By Stock
|
SPL |
Fierce Pharma - Coronavirus tracker:
|
|
UTexas80
|
0 |
260 |
21 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
0
|
260
|
21
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in substantial holding
|
|
UTexas80
|
8 |
3.3K |
1 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
8
|
3.3K
|
1
|
|
ASX - By Stock
|
SPL |
SPHRY: COVID Treatments: Remdesivir Disappoints, Antiviral SPL7013 & Monoclonal Antibodies Interest
|
|
UTexas80
|
6 |
2.4K |
31 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
6
|
2.4K
|
31
|
|
ASX - By Stock
|
SPL |
Re:
SPL chart
|
|
UTexas80
|
14 |
5.5K |
16 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
14
|
5.5K
|
16
|
|
ASX - By Stock
|
SPL |
A Neglected Treatment Space For COVID-19
|
|
UTexas80
|
5 |
2.6K |
23 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
5
|
2.6K
|
23
|
|
ASX - By Stock
|
SPL |
Re:
Prospects for Starpharma this new financial year in one word
|
|
UTexas80
|
22 |
6.4K |
1 |
05/07/20 |
05/07/20 |
ASX - By Stock
|
22
|
6.4K
|
1
|
|
ASX - By Stock
|
SPL |
Pandemic a catalyst for boosting commercial outcomes, says Starpharma boss
|
|
UTexas80
|
3 |
969 |
6 |
03/07/20 |
03/07/20 |
ASX - By Stock
|
3
|
969
|
6
|
|
Charts
|
SPL |
Re:
Starpharma
|
|
UTexas80
|
28 |
10K |
9 |
26/06/20 |
26/06/20 |
Charts
|
28
|
10K
|
9
|
|
ASX - By Stock
|
SPL |
Hot off the presses>>Starpharma's DEP Delivery Technology Edge Explained In AstraZeneca's Bcl-2/Bcl
|
|
UTexas80
|
1 |
957 |
2 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
1
|
957
|
2
|
|
Charts
|
SPL |
Re:
Starpharma
|
|
UTexas80
|
28 |
10K |
5 |
25/06/20 |
25/06/20 |
Charts
|
28
|
10K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
COVID-19: Gilead's Remdesivir Might Be As Good As It Gets
|
|
UTexas80
|
30 |
8.0K |
2 |
11/06/20 |
11/06/20 |
ASX - By Stock
|
30
|
8.0K
|
2
|
|
ASX - By Stock
|
SPL |
AstraZeneca Approaches Gilead About Potential Merger
|
|
UTexas80
|
6 |
2.4K |
1 |
08/06/20 |
08/06/20 |
ASX - By Stock
|
6
|
2.4K
|
1
|
|
ASX - By Stock
|
SPL |
COVID-19: Gilead's Remdesivir Might Be As Good As It Gets
|
|
UTexas80
|
30 |
8.0K |
4 |
05/06/20 |
05/06/20 |
ASX - By Stock
|
30
|
8.0K
|
4
|
|
ASX - By Stock
|
SPL |
Catching Coronavirus through the eyes...
|
|
UTexas80
|
0 |
291 |
1 |
15/05/20 |
15/05/20 |
ASX - By Stock
|
0
|
291
|
1
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013 outperformed Gilead against COVID-19
|
|
UTexas80
|
33 |
9.5K |
1 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
33
|
9.5K
|
1
|
|
ASX - By Stock
|
SPL |
Scientists say new disinfectant spray protects surfaces from coronavirus-f
|
|
UTexas80
|
0 |
425 |
1 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
0
|
425
|
1
|
|
ASX - By Stock
|
SPL |
Re:
A race we can’t afford to lose.
|
|
UTexas80
|
4 |
1.9K |
3 |
27/04/20 |
27/04/20 |
ASX - By Stock
|
4
|
1.9K
|
3
|
|
ASX - By Stock
|
SPL |
A race we can’t afford to lose.
|
|
UTexas80
|
4 |
1.9K |
4 |
26/04/20 |
26/04/20 |
ASX - By Stock
|
4
|
1.9K
|
4
|
|
ASX - By Stock
|
SPL |
AstraZeneca's fast-rising diabetes med Farxiga jumps into the COVID-19 fray
|
|
UTexas80
|
0 |
372 |
3 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
0
|
372
|
3
|
|
ASX - By Stock
|
SPL |
New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients.
|
|
UTexas80
|
0 |
378 |
3 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
0
|
378
|
3
|
|
ASX - By Stock
|
SPL |
Just curious
|
|
UTexas80
|
0 |
284 |
0 |
23/04/20 |
23/04/20 |
ASX - By Stock
|
0
|
284
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 shows significant activity against coronavirus
|
|
UTexas80
|
180 |
61K |
0 |
22/04/20 |
22/04/20 |
ASX - By Stock
|
180
|
61K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013 Aerosol spray OMG
|
|
UTexas80
|
14 |
5.3K |
2 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
14
|
5.3K
|
2
|
|
ASX - By Stock
|
SPL |
And then there is this... Funding continues to pour into biotech
|
|
UTexas80
|
0 |
419 |
5 |
18/04/20 |
18/04/20 |
ASX - By Stock
|
0
|
419
|
5
|
|
ASX - By Stock
|
SPL |
Wait...what....
|
|
UTexas80
|
0 |
406 |
5 |
18/04/20 |
18/04/20 |
ASX - By Stock
|
0
|
406
|
5
|
|
ASX - By Stock
|
SPL |
Seeking Alpha Breaking News: Starpharma to develop COVID-19 treatment
|
|
UTexas80
|
2 |
1.3K |
4 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
2
|
1.3K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
wow wow wow wow wow wow wow wow wow
|
|
UTexas80
|
60 |
20K |
2 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
60
|
20K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma: Beaten Up By COVID-19 For No Reason
|
|
UTexas80
|
14 |
4.7K |
2 |
28/03/20 |
28/03/20 |
ASX - By Stock
|
14
|
4.7K
|
2
|
|
ASX - By Stock
|
SPL |
Starpharma: Beaten Up By COVID-19 For No Reason
|
|
UTexas80
|
14 |
4.7K |
12 |
28/03/20 |
28/03/20 |
ASX - By Stock
|
14
|
4.7K
|
12
|
|
ASX - By Stock
|
SPL |
Interesting Part Deaux <- Has AstraZeneca lost its glow?
|
|
UTexas80
|
0 |
386 |
2 |
17/02/20 |
17/02/20 |
ASX - By Stock
|
0
|
386
|
2
|
|
ASX - By Stock
|
SPL |
Interesting --> AstraZeneca cans cancer pipeline efforts
|
|
UTexas80
|
3 |
2.1K |
3 |
17/02/20 |
17/02/20 |
ASX - By Stock
|
3
|
2.1K
|
3
|
|